Patients discharged with SGLT2 inhibitors presented more often with ST-elevation myocardial infarction and had worse LVEF at index hospitalisation but despite this, patients on SGLT2 inhibitors had lower rates of first hospitalisation for heart failure and lower mortality than patients not treated with SGLT2 inhibitors. The gene discussed is SLC5A2; the disease is heart failure.